{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination broadened antigen display, increasing the fraction of tumor proteins represented in the immunopeptidome.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |",
          "line_ref": "L28"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "This report summarizes pooled mouse experiments and proposed mechanisms; effects may vary by model and may not map one-to-one to human tumors."
    },
    {
      "claim_id": "C02",
      "claim": "Intratumoral mRNA vaccination induced a type I interferon state and increased PD-L1 pathway activity, supporting a rationale for combining with checkpoint blockade.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |",
          "line_ref": "L31"
        },
        {
          "quote": "| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |",
          "line_ref": "L32"
        },
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        }
      ],
      "caveat": "Mechanistic readouts were not uniformly strongest across all tested settings, so the magnitude and generality of these pathways may depend on the tumor model."
    },
    {
      "claim_id": "C03",
      "claim": "Type I interferon signaling was required for the sensitization effect, because blocking IFNAR1 eliminated the observed benefit.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "This requirement was shown within the experimental systems summarized here; translation to human tumors may differ and would require prospective clinical testing."
    },
    {
      "claim_id": "C04",
      "claim": "In a retrospective metastatic patient cohort receiving ICI treatment, prior SARS-CoV-2 mRNA vaccination was associated with improved survival.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        },
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "- The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "Because the human comparison is retrospective with variable vaccination timing and heterogeneous tumor types, the survival association should not be interpreted as causal."
    }
  ]
}
